HK1063012A1 - Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders - Google Patents
Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disordersInfo
- Publication number
- HK1063012A1 HK1063012A1 HK04105484A HK04105484A HK1063012A1 HK 1063012 A1 HK1063012 A1 HK 1063012A1 HK 04105484 A HK04105484 A HK 04105484A HK 04105484 A HK04105484 A HK 04105484A HK 1063012 A1 HK1063012 A1 HK 1063012A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- alzheimer
- treatment
- inhibitors
- napthoquinone
- neurodegenerative disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0117326.9A GB0117326D0 (en) | 2001-07-16 | 2001-07-16 | Napthoquinone-type inhibitors of protein aggregation |
PCT/GB2002/003269 WO2003007933A1 (en) | 2001-07-16 | 2002-07-16 | Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1063012A1 true HK1063012A1 (en) | 2004-12-10 |
Family
ID=9918593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK04105484A HK1063012A1 (en) | 2001-07-16 | 2004-07-24 | Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders |
Country Status (13)
Country | Link |
---|---|
US (1) | US7605179B2 (de) |
EP (1) | EP1408952B1 (de) |
JP (1) | JP5147157B2 (de) |
CN (1) | CN1313088C (de) |
AT (1) | ATE361067T1 (de) |
AU (1) | AU2002317354B2 (de) |
CA (1) | CA2451422C (de) |
DE (1) | DE60219917T2 (de) |
ES (1) | ES2287292T3 (de) |
GB (1) | GB0117326D0 (de) |
HK (1) | HK1063012A1 (de) |
SG (1) | SG148846A1 (de) |
WO (1) | WO2003007933A1 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
AU2004251511A1 (en) * | 2003-06-23 | 2005-01-06 | Neurochem (International) Limited | Treatment of protein aggregation disorders |
WO2005053609A2 (en) * | 2003-11-26 | 2005-06-16 | Guilford Pharmaceuticals Inc. | Methods of nad+-dependent deacetylase inhibitors |
WO2006007864A1 (en) * | 2004-07-17 | 2006-01-26 | Max Planck Geselllschaft Zur Förderung Der Wissenschaft | Treating neurodegenerative conditions |
FR2874923B1 (fr) * | 2004-09-07 | 2006-10-27 | Trophos Sa | Application a titre de medicaments de derives du 3, 5-seco-4-nor-cholestane, compositions pharmaceutiques les renfermant, nouveaux derives et leur procede de preparation |
CN101084204B (zh) | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
JP4734602B2 (ja) | 2004-12-21 | 2011-07-27 | Dowaエレクトロニクス株式会社 | 保存安定性に優れた窒化鉄系磁性粉末 |
JP4822312B2 (ja) * | 2005-05-13 | 2011-11-24 | 学校法人慶應義塾 | ナフトキノン誘導体化合物 |
KR100699945B1 (ko) * | 2005-11-24 | 2007-03-26 | (주) 디지탈바이오텍 | 나프토퀴논계 화합물을 함유하는 인지기능 장애의 예방 및 치료용 조성물 |
ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
US8263589B2 (en) | 2006-03-29 | 2012-09-11 | Wista Laboratories Ltd. | Inhibitors of protein aggregation |
US20110201686A1 (en) * | 2006-06-23 | 2011-08-18 | Yousef Al-Abed | Inhibitors of ASS and Synuclein Aggregation |
KR20090127260A (ko) * | 2007-04-05 | 2009-12-10 | 제이-오일 밀스, 인코포레이티드 | 신경 안정제 및 기능성 식품 |
JP2010538611A (ja) * | 2007-09-07 | 2010-12-16 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | タウタンパク質スクリーニングアッセイ |
EP2060256A1 (de) * | 2007-11-16 | 2009-05-20 | Gnosis S.p.A. | Auf Menaquinolen basierende pharmazeutische und nutrazeutische Zusammensetzungen |
GB0816269D0 (en) * | 2008-09-05 | 2008-10-15 | Univ Ramot | Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of alzheimers disease |
JP2013529181A (ja) | 2010-03-25 | 2013-07-18 | ザ ジェイ. デヴィッド グラッドストーン インスティテューツ | 神経障害を治療するための組成物および方法 |
US9320793B2 (en) * | 2010-07-14 | 2016-04-26 | Acumen Pharmaceuticals, Inc. | Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42 |
EA201300215A1 (ru) * | 2010-08-06 | 2013-07-30 | Эдисон Фармасьютикалз, Инк. | Лечение митохондриальных болезней нафтохинонами |
US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
KR101888713B1 (ko) | 2011-02-11 | 2018-08-14 | 위스타 레보레이토리스 리미티드 | 페노티아진 디아미늄 염 및 이의 용도 |
JP6038122B2 (ja) | 2011-04-21 | 2016-12-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 機能性磁性ナノ粒子、ならびにアミロイド沈着物および神経原繊維濃縮体の画像処理における使用 |
WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
WO2013051266A1 (ja) | 2011-10-03 | 2013-04-11 | 独立行政法人国立長寿医療研究センター | タウ凝集阻害剤 |
US9938560B2 (en) | 2012-02-05 | 2018-04-10 | Biodesy, Inc. | Methods for identifying modulators of Ras using nonlinear techniques |
HUE048780T2 (hu) | 2012-08-16 | 2020-09-28 | Ipierian Inc | Tauopátia kezelésére szolgáló módszerek |
WO2014039917A1 (en) | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
WO2014066744A2 (en) | 2012-10-25 | 2014-05-01 | True North Therapeutics, Inc. | Anti-complement c1s antibodies and uses thereof |
US8945562B2 (en) | 2012-11-02 | 2015-02-03 | True North Therapeutics, Inc. | Anti-complement C1s antibodies |
US9907799B2 (en) | 2013-04-02 | 2018-03-06 | The Doshisha | Tau aggregation inhibitor |
EA039554B1 (ru) | 2013-06-10 | 2022-02-09 | АйПИЕРИАН, ИНК. | Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости |
CN105659087B (zh) * | 2013-06-13 | 2019-09-17 | 比奥德赛公司 | 筛选靶向靶生物实体的候选生物实体的方法 |
US20150166476A1 (en) * | 2013-12-17 | 2015-06-18 | Yi-Cheng Chen | Methods for treating neurodegenerative diseases associated with aggregation of amyloid-beta |
EP3237906B8 (de) | 2014-12-23 | 2020-10-28 | Bluelight Therapeutics, Inc. | Befestigung von proteinen an schnittstellen zur verwendung in nicht-linearer optischer detektion |
WO2019191773A1 (en) | 2018-03-30 | 2019-10-03 | Kaydence Pharma As | Rapidly improving vascular conditions by administering vitamin k |
CN113874078A (zh) | 2019-04-05 | 2021-12-31 | Tauc3生物制品有限公司 | 抗tauc3抗体及其应用 |
CN110025624B (zh) * | 2019-05-29 | 2021-04-02 | 济宁医学院附属医院 | 萘醌苷类化合物在老年痴呆中的应用及其药物制备 |
CN112778092B (zh) * | 2020-12-31 | 2023-03-24 | 玉溪健坤生物药业有限公司 | 一种还原型维生素k2的制备方法及其用途 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59175449A (ja) * | 1983-03-26 | 1984-10-04 | Kyushu Kogyo Daigaku | シコニンの製造法 |
JPS61143334A (ja) * | 1984-12-18 | 1986-07-01 | Mitsui Petrochem Ind Ltd | 5,8−ジヒドロキシ−1,4−ナフトキノン誘導体 |
US4897388A (en) * | 1988-12-20 | 1990-01-30 | Geriatric Research Institute, Inc. | Method of treating Alzheimer's disease |
DE69231222T2 (de) * | 1991-02-04 | 2001-03-01 | Ks Biomedix Ltd., Esher | Naphtochinonderivate zur Behandlung von chronischen Entzündungen |
ATE438716T1 (de) | 1991-12-06 | 2009-08-15 | Max Planck Gesellschaft | Verwendung von protein-kinasen zur diagnose und behandlung der alzheimer-krankheit |
AU708682B2 (en) | 1994-08-08 | 1999-08-12 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing Alzheimer's disease using phenothiazines and/or thioxanthenes |
JPH08193026A (ja) * | 1995-01-12 | 1996-07-30 | Teijin Ltd | アミロイドβ蛋白凝集・沈着阻害剤 |
DE19504003A1 (de) * | 1995-02-08 | 1996-08-14 | Martin Dr Kohlmeier | Verwendungen eines Vitamins der K-Gruppe |
GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
US5804601A (en) | 1995-04-10 | 1998-09-08 | Takeda Chemical Industries, Ltd. | Aromatic hydroxamic acid compounds, their production and use |
KR0180791B1 (ko) * | 1995-07-24 | 1999-05-15 | 김용옥 | 6-치환-5,8-디옥시-1,4-나프토퀴논 유도체, 그의 제조방법 및 그의 항암제로서의 용도 |
JP3809014B2 (ja) * | 1998-05-22 | 2006-08-16 | 花王株式会社 | 養毛・育毛剤 |
US20020040011A1 (en) | 2000-06-01 | 2002-04-04 | Brown Dennis M. | Naphthoquinone compositions and uses thereof |
US20020016372A1 (en) | 2000-07-31 | 2002-02-07 | Allison Anthony Clifford | Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
US6953974B2 (en) * | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
ES2736160T3 (es) | 2004-09-23 | 2019-12-26 | Wista Lab Ltd | Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT) |
-
2001
- 2001-07-16 GB GBGB0117326.9A patent/GB0117326D0/en not_active Ceased
-
2002
- 2002-07-16 EP EP02745640A patent/EP1408952B1/de not_active Expired - Lifetime
- 2002-07-16 DE DE60219917T patent/DE60219917T2/de not_active Expired - Lifetime
- 2002-07-16 ES ES02745640T patent/ES2287292T3/es not_active Expired - Lifetime
- 2002-07-16 AU AU2002317354A patent/AU2002317354B2/en not_active Expired
- 2002-07-16 AT AT02745640T patent/ATE361067T1/de active
- 2002-07-16 US US10/483,266 patent/US7605179B2/en not_active Expired - Lifetime
- 2002-07-16 CN CNB028177207A patent/CN1313088C/zh not_active Expired - Lifetime
- 2002-07-16 JP JP2003513541A patent/JP5147157B2/ja not_active Expired - Lifetime
- 2002-07-16 WO PCT/GB2002/003269 patent/WO2003007933A1/en active IP Right Grant
- 2002-07-16 SG SG200600959-1A patent/SG148846A1/en unknown
- 2002-07-16 CA CA2451422A patent/CA2451422C/en not_active Expired - Lifetime
-
2004
- 2004-07-24 HK HK04105484A patent/HK1063012A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2287292T3 (es) | 2007-12-16 |
AU2002317354B2 (en) | 2007-07-19 |
EP1408952A1 (de) | 2004-04-21 |
DE60219917T2 (de) | 2008-01-17 |
WO2003007933A1 (en) | 2003-01-30 |
CA2451422C (en) | 2010-10-19 |
ATE361067T1 (de) | 2007-05-15 |
CN1313088C (zh) | 2007-05-02 |
EP1408952B1 (de) | 2007-05-02 |
GB0117326D0 (en) | 2001-09-05 |
US7605179B2 (en) | 2009-10-20 |
DE60219917D1 (de) | 2007-06-14 |
SG148846A1 (en) | 2009-01-29 |
CA2451422A1 (en) | 2003-01-30 |
JP2004534854A (ja) | 2004-11-18 |
US20050107472A1 (en) | 2005-05-19 |
JP5147157B2 (ja) | 2013-02-20 |
CN1553800A (zh) | 2004-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1063012A1 (en) | Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders | |
NO20053855L (no) | 1-fenylalkankarboksylsyrederivater til behandling av neurodegenerative sykdommer. | |
ES2170104T3 (es) | Inhibidores de la produccion de proteinas de beta-amiloide. | |
DK1465626T3 (da) | Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf | |
GB2364059A (en) | Beta-Secretase enzyme compositions and methods | |
NO20034056D0 (no) | Proliferative sykdommer | |
EP2213684A3 (de) | Nogo-A-Antikörper für die Behandlung von Alzheimer-Krankheit | |
WO2005004803A3 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease | |
NO20035474D0 (no) | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav | |
WO2004014953A3 (en) | Anti-myelin associated glycoprotein (mag) antibodies | |
IL169889A0 (en) | Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin | |
NO20015247L (no) | Glysinspaltingssysteminhibitorer som potensielle antipsykotika | |
ATE522230T1 (de) | Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit | |
NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
BR0314541A (pt) | Tratamento de demência e doença de parkinson | |
MY135225A (en) | Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders | |
WO2004096199A3 (en) | Regulation of guanine nucleotide exchange factor | |
WO2004047854A3 (en) | Methods for the treatment of alzheimers disease and compositions therefore |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20220715 |